Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07037433 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Name: Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — clinical trial record (NCT07037433)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MARITIME-CV

StatusRecruiting

PhasePhase 3

SponsorAmgen

Started2025-07-25

View on ClinicalTrials.gov ↗

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Amendment history 5 changes detected by DataLookout

2026-07-11

Trial sites expanded: 774 → 781 locations

2026-05-30

Trial sites expanded: 769 → 772 locations

2026-05-23

Trial sites expanded: 766 → 769 locations

2026-05-12

Trial sites expanded: 759 → 765 locations

2026-04-21

Trial sites expanded: 726 → 758 locations

Trial Details

NCT Number	NCT07037433
Lead Sponsor	Amgen
Conditions	Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Enrollment	12,800 participants
Start Date	2025-07-25
Primary Completion	2028-06-30 (estimated)
Study Completion	2030-09-29 (estimated)
Updated on ClinicalTrials.gov	2026-09-03